Clara Andrezza Crisóstomo Bezerra Costa

Clara Andrezza Crisóstomo Bezerra Costa

Auto-generated profile, based on publicly available information

Clara Andrezza Crisóstomo Bezerra Costa

Department of Chemistry, Federal Institute of Alagoas, Maceió, Brazil

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2022 in South African Journal of Botany
Verified
Journal Article
Open access
RCRenata da Silva Carneiro
Renata da Silva Carneiro
MCMarta Rejane Canuto
Marta Rejane Canuto
LRLara Kelly Ribeiro
Lara Kelly Ribeiro
DFDanniel Cabral Leão Ferreira
Danniel Cabral Leão Ferreira
AAAmanda Fonseca Costa Assunção
Amanda Fonseca Costa Assunção
VUValdiléia Teixeira Uchôa
Valdiléia Teixeira Uchôa

11 July 2022 in Journal of Toxicology and Environmental Health, Part A
Verified
Journal Article
Closed access
PMPenina Sousa Mourão
Penina Sousa Mourão
RGRafael de Oliveira Gomes
Rafael de Oliveira Gomes
CCClara Andrezza Crisóstomo Bezerra Costa
Clara Andrezza Crisóstomo Bezerra Costa
OMOrlando Francisco da Silva Moura
Orlando Francisco da Silva Moura
HSHerbert Gonzaga Sousa
Herbert Gonzaga Sousa
VUValdiléia Teixeira Uchôa
Valdiléia Teixeira Uchôa
Cecropia pachystachya Tréc., popularly known as embaúba, belongs to the Cecropiaceae family and is used by the native population in the treatment of bronchitis, asthma, high blood pressure, fever, and as a diuretic. The pharmacological actions including anti-inflammatory, antioxidant, cardiotonic and sedative were previously reported. The objective of this study was to (1) isolate and identify bioactive compounds extracted from the ethanolic extract of C. pachystachya roots (ERCP), as well as (2) verify the affinity of these metabolites with the enzymes 5-lipoxygenase (5-LOX) and α-1-antitrypsin through in silico tests. Isolation and/or identification were performed using GC-MS, HPLC, Infrared (IR), and nuclear magnetic resonance (NMR) techniques. After isolation and identification of the active compounds, these substances were subjected to the in silico investigation that proceeded by performing PreADMET simulations and molecular docking calculations. The bioactive compounds identified were 1-(+)-ascorbic acid 2,6-dihexadecanoate, ethyl hexadecanoate, ethyl (9E,12E)-octadec-9,12-dienoate, ethyl (Z)-octadec-9-enoate and ethyl octadecanoate by GC-MS; chlorogenic acid, catechin, epicatechin, syringaldehyde by HPLC; β-sitosterol, sitostenone, beccaridiol, tormentic acid, lupeol, α- and β-amyrin by classical chromatography, IR, 1H and 13C NMR techniques. The ADMET (absorption, distribution, metabolism, excretion, and toxicity) properties were determined for each bioactive compound. Tormentic acid demonstrated a greater affinity for 5-LOX enzyme while sitostenone demonstrated a higher affinity for the α-1-antitrypsin enzyme. Our findings demonstrated a diverse range of secondary metabolites isolated from C. pachystachya that showed relevant interactions with the enzymes 5-LOX and α-1-antitrypsin. Thus, “embaúba” may be employed in in vivo experimental studies as a form of alternative treatment for chronic lung diseases. Abbreviations: ADT: Autodock Tools; BBB: Blood-brain barrier; CaCo2: Human colonic adenocarcinoma cells; CC: Classic/open Column; TLC: Thin Layer Chromatography; CD40: Differentiation Cluster 40; CENAUREMN: Centro Nordestino de Aplicação e Uso da Ressonância Magnética Nuclear; GC-MS: Gas Chromatography coupled to mass spectrometry; HPLC: High-Perfomance Liquid Chromatography; CYP2C9, CYP2C19, CYP2D6 and CYP3A4: Cytochrome P450 isoenzymes; COPD: Chronic Obstructive Pulmonary Disease; DRX-500: X-Ray Diffraction – 500; ERCP: Ethanolic extract of the roots of C. pachystachya; FAPEPI: Fundação de Amparo à Pesquisa do Piauí; HIA: Human Intestinal Absorption; IR: Infrared; Ki: Inhibition constant; 5-LOX: 5-Lipoxygenase; mM: miliMolar; nM: nanoMolar; OECD423: acute toxic class method; PDB: Protein Data Bank; P-gP: P-glycoprotein; PM2,5: Small inhalable particles 2,5; PPB: Plasm Protein Binding; PreADMET: Prediction Absorption, Distribution, Metabolization, Excretion and Toxicity; NMR: Nuclear Magnetic Resonance; +S9: with metabolic activation; -S9: no metabolic activation; SisGen: Sistema Nacional de Gestão de Patrimônio Genético e do Conhecimento Tradicional Associado; RT: Retention time; TA100: Ames test with TA100 cells line; TA1535: Ames test with cells of the TA1535 cell line; UESPI: State University of Piauí; V79: lung fibroblast cells; ΔG: Gibbs free energy (Kcal/mol); μM: microMolar.

2 March 2021 in Research, Society and Development
Verified
Journal Article
Open access
PDF file
TLTatiana de Oliveira Lopes
Tatiana de Oliveira Lopes
JSJaqueline Fernanda de Sousa Silva
Jaqueline Fernanda de Sousa Silva
RSRudielson dos Santos Silva
Rudielson dos Santos Silva
RCRenata da Silva Carneiro
Renata da Silva Carneiro
AOAntônio Rafael de Oliveira
Antônio Rafael de Oliveira
VUValdiléia Teixeira Uchôa
Valdiléia Teixeira Uchôa
Herbal medicines based on Ginkgo biloba L. and Bacopa monnieri L. are used to improve memory and cognitive function. The quality control and anticholinesterase activity of the herbal medicines prepared from G. biloba and B. monnieri were evaluated which are commercialized in handling pharmacies. Samples of herbal medicines based on G. biloba and B. monnieri were obtained from handling pharmacies in Teresina-PI, submitted to labeling analysis and anticholinesterase activity. The phytochemical study was performed by preliminary prospecting, TLC and HPLC. The tests physicochemical and microbiological analyses were made according to the Pharmacopoeia 2010. It was observed that the labeling, foreign material, disintegration, and microbiological parameters were in accordance with ANVISA standards. The colorimetric tests were uniform in the samples of B. monnieri and variable of G. biloba. The average weight evaluation shows that the G1 and B3 samples have capsular content above that described in the labeling and presented pH values ​​different. Among the thermogravimetric profiles, the mass losses of samples G1 and B3 showed values ​​with high ash content, suggesting adulterations. Phytochemical prospecting showed flavonoids as common secondary metabolites in both species, corroborating with TLC and HPLC analysis, which identified the compounds chlorogenic acid, rutin, myricetin and quercetin. The samples G4, B2 and B5 present metabolites capable of inhibiting the enzyme acetylcholinesterase with IC50 of 0.8540 mg/mL, 0.9650 mg/mL and 1.8221×10-5 mg/mL, respectively. The samples G1 and B3 of G. biloba and B. monnieri, did not obey some parameters of quality control for herbal medicines according to the criteria of the Brazilian Pharmacopeia.

1 January 2023 in Revista Virtual de Química
Verified
Journal Article
Closed access
ANAntonio R. da Silva Neto
Antonio R. da Silva Neto
ASAmanda C. de S. O. Sousa
Amanda C. de S. O. Sousa
LCLuiz F. R. Camboim
Luiz F. R. Camboim
JSJoão P. R da Silva
João P. R da Silva
AFAntônio L. M. Maia Filho
Antônio L. M. Maia Filho
VUValdiléia T. Uchôa
Valdiléia T. Uchôa

11 July 2023 in South African Journal of Botany
Verified
Journal Article
Open access
MSMaria Lanna Souza da Silva
Maria Lanna Souza da Silva
PMPenina Sousa Mourão
Penina Sousa Mourão
VRVitória Raquel da Silva Reis
Vitória Raquel da Silva Reis
CCClara Andrezza Crisóstomo Bezerra Costa
Clara Andrezza Crisóstomo Bezerra Costa
OMOrlando Francisco da Silva Moura
Orlando Francisco da Silva Moura
AMAntônio Luiz Martins Maia-Filho
Antônio Luiz Martins Maia-Filho

3 April 2024
Verified
Book Chapter
Closed access
PDF file
PMPenina S. Mourão
Penina S. Mourão
RGRafael de O. Gomes
Rafael de O. Gomes
CCClara A. C. B. Costa
Clara A. C. B. Costa
OMOrlando F. da S. Moura
Orlando F. da S. Moura
JFJOHNNATAN Duarte de FREITAS
JOHNNATAN Duarte de FREITAS
VUValdiléia T. Uchôa
Valdiléia T. Uchôa
The use of medicinal plants has been widely employed in the treatment of several diseases. Cecropia pachystachya Tréc. (Cecropiaceae), popularly known as “embaúba,” is a medicinal plant used for the treatment of asthma, cough, hypertension, diabetes, inflammation, bronchodilator effect, and as a cardiotonic, among other uses. The leaves have a bronchodilator activity and cardiovascular effect, it has cardiotonic and sedative actions, antioxidant properties, and anti-inflammatory and apoptotic activity. Some compounds have already been related such as chlorogenic acid, isoorientin, orientin, catechin, epicatechin, isoquercitrin, isovitexin, sitostero, α-amyrin, and ursolic; pomolic, oleanolic, and tormentic acids; and ethyl hexadecanoate, L-(+)-ascorbic acid-2,6-dihexadecanoate, (9E,12E)-octadec-9,12-dienoate, (Z)-octadec-9-enoate, ethyl octadecanoate, sitostenone, beccaridiol, lupeol, and syringaldehyde. That said, the aim of this work is to carry out the identification of chemical compounds present in the ethyl extract of C. pachystachya leaves and to verify the PreADMET properties and the interaction of these compounds with 5-LOX and α-1-antitrypsin enzymes through in silico tests. Initially, the extract was prepared with 99% ethanol, then this extract was analyzed by GC-MS to identify chemicals. Once these molecules were identified, their structures were subjected to predictive ADMET tests in silico and molecular docking tests with the target enzymes of chronic respiratory diseases (5-LOX and α-1-antitrypsin). Software such as Chimera version 1.15 and Autodock and Autodock Tools version 1.5.6 were used for the realization of the molecular docking calculus. In GC-MS analysis, a total of 62 compounds were identified, with the substances ethyl hexadecanoate (32), phytol (37), linoleic acid (42), tridec-2-inyl 2,2-dichloroacetate (43), and ethyl octadecanoate (45) showing the highest relative percentage area. ADMET properties were determined for each molecule, and all fit the parameters of the rule of five and can be classified as a drug. Among the molecular docking calculations, the complexes with linoleic acid and phytol showed better interaction energy values for the enzyme 5-LOX and α-1-antitrypsin, respectively. Thus, we have results of scientific relevance and the need for further tests (in vivo and/or in vitro) to prove in fact the therapeutic action of embaúba in chronic respiratory diseases. <!----> <!----> <!----> <!---->